Single User License
INR 102030
Site License
INR 204060
Corporate User License
INR 306090

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


The Medicines Company-Product Pipeline Review-2015

The Medicines Company-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

The Medicines Company-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'The Medicines Company-Product Pipeline Review-2015', provides an overview of the The Medicines Company's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of The Medicines Company's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of The Medicines Company including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of The Medicines Company's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the The Medicines Company's pipeline products

Reasons To Buy

Evaluate The Medicines Company's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of The Medicines Company in its therapy areas of focus

Identify new drug targets and therapeutic classes in the The Medicines Company's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of The Medicines Company and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of The Medicines Company

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of The Medicines Company and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

The Medicines Company Snapshot 6

The Medicines Company Overview 6

Key Information 6

Key Facts 6

The Medicines Company-Research and Development Overview 7

Key Therapeutic Areas 7

The Medicines Company-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Combination Treatment Modalities 12

Pipeline Products-Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

The Medicines Company-Pipeline Products Glance 15

The Medicines Company-Late Stage Pipeline Products 15

Pre-Registration Products/Combination Treatment Modalities 15

Phase III Products/Combination Treatment Modalities 16

The Medicines Company-Clinical Stage Pipeline Products 17

Phase I Products/Combination Treatment Modalities 17

The Medicines Company-Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

The Medicines Company-Drug Profiles 19

bivalirudin 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

cangrelor 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

clevidipine 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

(meropenem+ RPX-7009) 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

(biapenem + RPX-7009) 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

ABP-700 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

MDCO-216 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

oritavancin diphosphate 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

carboetomidate 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

fibrinogen (recombinant) 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

methoxycarbonyl carboetomidate 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

methoxycarbonyl etomidate 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

tigecycline 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

The Medicines Company-Pipeline Analysis 38

The Medicines Company-Pipeline Products by Target 38

The Medicines Company-Pipeline Products by Route of Administration 39

The Medicines Company-Pipeline Products by Molecule Type 40

The Medicines Company-Pipeline Products by Mechanism of Action 41

The Medicines Company-Recent Pipeline Updates 42

The Medicines Company-Dormant Projects 50

The Medicines Company-Discontinued Pipeline Products 51

Discontinued Pipeline Product Profiles 51

clopidogrel bisulfate 51

MDCO-2010 51

The Medicines Company-Company Statement 52

The Medicines Company-Locations And Subsidiaries 54

Head Office 54

Other Locations & Subsidiaries 54

Appendix 58

Methodology 58

Coverage 58

Secondary Research 58

Primary Research 58

Expert Panel Validation 58

Contact Us 58

Disclaimer 59

List of Tables

The Medicines Company, Key Information 6

The Medicines Company, Key Facts 6

The Medicines Company-Pipeline by Indication, 2015 9

The Medicines Company-Pipeline by Stage of Development, 2015 10

The Medicines Company-Monotherapy Products in Pipeline, 2015 11

The Medicines Company-Combination Treatment Modalities in Pipeline, 2015 12

The Medicines Company-Partnered Products in Pipeline, 2015 13

The Medicines Company-Partnered Products/ Combination Treatment Modalities, 2015 14

The Medicines Company-Pre-Registration, 2015 15

The Medicines Company-Phase III, 2015 16

The Medicines Company-Phase I, 2015 17

The Medicines Company-Preclinical, 2015 18

The Medicines Company-Pipeline by Target, 2015 38

The Medicines Company-Pipeline by Route of Administration, 2015 39

The Medicines Company-Pipeline by Molecule Type, 2015 40

The Medicines Company-Pipeline Products by Mechanism of Action, 2015 41

The Medicines Company-Recent Pipeline Updates, 2015 42

The Medicines Company-Dormant Developmental Projects,2015 50

The Medicines Company-Discontinued Pipeline Products, 2015 51

The Medicines Company, Other Locations 54

The Medicines Company, Subsidiaries 55

List of Figures

The Medicines Company-Pipeline by Top 10 Indication, 2015 8

The Medicines Company-Pipeline by Stage of Development, 2015 10

The Medicines Company-Monotherapy Products in Pipeline, 2015 11

The Medicines Company-Combination Treatment Modalities in Pipeline, 2015 12

The Medicines Company-Partnered Products in Pipeline, 2015 13

The Medicines Company-Pipeline by Top 10 Target, 2015 38

The Medicines Company-Pipeline by Top 10 Route of Administration, 2015 39

The Medicines Company-Pipeline by Top 10 Molecule Type, 2015 40

The Medicines Company-Pipeline Products by Top 10 Mechanism of Action, 2015 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of The Medicines Company; The Medicines Company - Key Therapeutics; The Medicines Company - Pipeline Overview and Promising Molecules; The Medicines Company - News; The Medicines Company - Latest Updates; The Medicines Company - Pipeline; The Medicines Company - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com